Atara Biotherapeutics Receives Buy Rating Amidst Positive FDA Review and Solid Financial Outlook
Atara Biotherapeutics Analyst Ratings
Goldman Sachs Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $11
Atara Biotherapeutics Hold Rating Based on Promising Preclinical Data and Awaited Clinical Trials
Stifel Nicolaus Sticks to Its Hold Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings
Atara Biotherapeutics: A Balanced Hold Amidst FDA Approval Prospects and Valuation Uncertainties
Analysts Have Conflicting Sentiments on These Healthcare Companies: Deciphera Pharmaceuticals (DCPH), Atara Biotherapeutics (ATRA) and Nkarta (NKTX)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cytek Biosciences (CTKB), Elanco Animal Health (ELAN) and Atara Biotherapeutics (ATRA)
Buy Rating Affirmed for Atara Biotherapeutics on Strong Pipeline and Financial Health
Atara Biotherapeutics Analyst Ratings
Stifel Adjusts Atara Biotherapeutics Price Target to $2.30 From $4.80, Maintains Hold Rating
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA) and Embecta Corporation (EMBC)
Analysts Offer Insights on Healthcare Companies: Affimed (AFMD) and Atara Biotherapeutics (ATRA)
Atara Biotherapeutics (ATRA) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (ATRA), Moderna (MRNA) and Madrigal Pharmaceuticals (MDGL)
Atara Biotherapeutics (ATRA) Gets a Hold From H.C. Wainwright
Atara Biotherapeutics Analyst Ratings
Goldman Sachs Sticks to Its Sell Rating for Atara Biotherapeutics (ATRA)
Atara Biotherapeutics Analyst Ratings